Post-marketing Surveillance Study of an Inactivated Split-Virion Influenza Vaccine in Korea
Jaewon Huh, Sang Hyuk, Hyun-Kyun Kim, Bhavyashree Gunapalaiah, Hans L. Bock, on behalf of the Fluarix-054 Study Group
Abstract
Jaewon Huh, Sang Hyuk, Hyun-Kyun Kim, Bhavyashree Gunapalaiah, Hans L. Bock, on behalf of the Fluarix-054 Study Group
Abstract
Purpose : This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002. Methods : Eight hundred and eighty three subjects aged 6 months received a single dose of the vaccine; an additional dose was administered to those aged 6 years: 34.7%), fever (6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by 4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria). Conclusion : Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Purpose : This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002. Methods : Eight hundred and eighty three subjects aged 6 months received a single dose of the vaccine; an additional dose was administered to those aged 6 years: 34.7%), fever (6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by 4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria). Conclusion : Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.
Key concepts: Reactogenicity, Medicine, Adverse effect, Vaccination, Immunogenicity, Influenza vaccine, Immunization, Postmarketing surveillance